# Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma

> **NCT06044506** · PHASE1 · RECRUITING · sponsor: **Dr Cipto Mangunkusumo General Hospital** · enrollment: 3 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Autologous Natural Killer Cell Therapy
- **DEVICE:** Clinimacs Plus

## Key facts

- **NCT ID:** NCT06044506
- **Lead sponsor:** Dr Cipto Mangunkusumo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-29
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06044506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06044506, "Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06044506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*